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therefore careful selection of the appropriate assay 
is an important clinical and research consider-
ation.
Benjamin M. Scirica, M.D., M.P.H. 
Eugene Braunwald, M.D. 
Deepak L. Bhatt, M.D., M.P.H.
Brigham and Women’s Hospital 
Boston, MA 
dlbhattmd@post.harvard.edu
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. Scirica BM, Raz I, Cavender MA, et al. Outcomes of patients 
with type 2 diabetes and known congestive heart failure treated 
with saxagliptin: analyses of the SAVOR-TIMI 53 Study. Circula-
tion 2013;128:A17503. abstract.
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Drs. White and Zannad Reply: Standl inquires 
about findings in the EXAMINE trial regarding 
incident heart failure, since these exploratory 
data were not part of the article on our primary 
results. Because concerns have been raised re-
cently about other DPP-4 inhibitors and increased 
rates of hospitalization among patients with 
heart failure, we have initiated analyses of heart-
failure outcomes in our trial. In patients with 
type 2 diabetes and a recent acute coronary syn-
drome, including patients with a history of heart 
failure and those with elevated baseline levels of 
N-terminal pro–brain natriuretic peptide, cardio-
vascular outcomes inclusive of hospitalization for 
heart failure were not increased with alogliptin 
as compared with placebo. In addition, alogliptin 
neither induced new-onset heart failure nor 
worsened heart-failure outcomes in patients with 
a history of heart failure before randomization. 
We will continue to analyze results related to this 
important question in our trial.
William B. White, M.D.




Centre Hospitalier Universtaire 
Nancy, France
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
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Preparing for Responsible Sharing of Clinical Trial Data
To the Editor: Mello et al. (Oct. 24 issue)1 iden-
tify ensuring the responsible use of data as a key 
aspect of any system for expanded access to par-
ticipant-level data. In their careful framework for 
considering the legal, ethical, and policy impli-
cations of such sharing, however, they omit a 
powerful mechanism to meet this aim. Open 
computer code facilitates replication, which both 
advances knowledge2 and holds powerful inter-
ests accountable.3
Regardless of which of the four proposed 
models are adopted, data-use agreements should 
require data requesters to publish their computer 
code alongside any analysis. The program should 
be complete, in that it takes as its input the pro-
vided trial data and finishes by providing every 
table, figure, and summary statistic reported in 
the final paper.
Just as proposals for an increase in the level 
of shared clinical trial data use openness as a 
mechanism to hold data generators accountable, 
openness can hold data requesters accountable. 
If scientists can make progress in ensuring the 
replicability of studies that include the use of 
genetically modified mice,4 surely the far easier 
task of ensuring replicable reanalyses can be 
achieved.
Ari B. Friedman, M.S.
Leonard Davis Institute of Health Economics 
Philadelphia, PA 
arib@alumni.upenn.edu
No potential conflict of interest relevant to this letter was re-
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To the Editor: Mello and colleagues outline the 
potential benefits and risks of participant-level 
data sharing. They highlight technical and ethi-
cal concerns as sponsors and investigators move 
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these initiatives forward. However, insofar as in-
novations overcome important limitations such 
as intellectual property and privacy, two points 
remain relevant.
First, implementing responsible participant-
level data sharing is a moral imperative to ac-
celerate discovery with limited resources and to 
address the ominous quality of scientific output. 
Current siloed and fragmented science fails to 
answer important questions in an increasingly 
complex world.1 Conversely, participant-level data 
sharing shifts the paradigm to collaboration, 
which enables the pooling of skills, insights, and 
resources from different teams.2
Second, concurrently with this wave of data 
availability, computational tools can now tackle 
big data opportunities. It is possible to manage 
large-scale data sets, reformat them to link and 
integrate, and construct analytic algorithms in 
an effective and timely fashion.3 A perfect storm 
is exposing a large volume of data to new tools, 
paving the way to groundbreaking collaboration 
across networks to increase productivity and 
boost the quality of medical science.
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Access to Patient-Level Trial Data
To the Editor: The Chief Medical Officers 
Roundtable (CMOR), of which we are members, 
welcomes the Perspective article by Eichler et al. 
(Oct. 24 issue),1 who are representatives of the 
European Medicines Agency (EMA), on access to 
patient-level trial data. CMOR formulates posi-
tions on medical topics, and its members include 
chief medical officers of major biopharmaceuti-
cal companies. CMOR supports a transparent, 
harmonized process for access to patient-level 
clinical trial data.
Any approach to clinical trial data sharing 
must be in the interest of patients. Data sharing 
should be based on two tenets. First, principles 
should apply uniformly to all who generate 
clinical trial data — industry, academia, regula-
tors, health systems, foundations, and others. 
There will be little benefit to patients if access 
does not occur across sectors. Second, the re-
sponsible release of data requires input from 
independent experts and agreements to respect 
confidentiality, promote scientific excellence, re-
frain from misleading conclusions (which can 
harm patients if they discontinue beneficial treat-
ment),2 and safeguard future innovation by re-
taining incentives for investigators.
Access should be determined after the sub-
mission of a proposal to a panel that includes 
independent experts. Evaluation should be based 
on scientific merit, relevance, researcher qualifi-
cations, potential conflicts of interest, and plans 
for dissemination of findings after peer review. 
To this end, the CMOR supports the consensus 
study launched by the Institute of Medicine. It is, 
to our knowledge, the only broadly inclusive 
initiative and has the international participation 
of academia, industry, the National Institutes of 
Health, the Food and Drug Administration, the 
EMA, journals, patient organizations, founda-
tions, and others.2
Contrary to the assertion by Eichler et al. that 
industry opposes the sharing of patient-level data, 
many companies are creating processes like those 
mentioned above.2 Industry already shares re-
sults through ClinicalTrials.gov, public websites, 
and scientific publications.3
Furthermore, the European Federation of 
Pharmaceutical Industries and Associations and 
the Pharmaceutical Research and Manufacturers 
of America have moved beyond the status quo in 
adopting the Principles for Responsible Clinical 
Trial Data Sharing, which will be implemented 
in January 2014 and include the following major 
points.4 First, patient- and study-level clinical 
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